Renal denervation is a minimally invasive procedure that aims to decrease the sympathetic nerve activity to the kidneys. It involves threading a catheter through the arteries until it reaches the renal arteries, which supplies blood to the kidneys. The device then delivers energy to the nerves in the vessel wall to disrupt the signals that can cause high blood pressure. The energy can be delivered through various methods, such as radiofrequency ablation, ultrasound, and more recently, direct injection of chemicals or new methodologies based on percutaneous delivery systems. The rationale behind renal denervation comes from the understanding that the kidneys play a significant role in blood pressure regulation. Overactive renal nerves can lead to increased systemic blood pressure. By disrupting these overactive nerve pathways, renal denervation can potentially help to sustainably lower blood pressure in people for whom other treatments have failed. Although the procedure showed promise in early clinical trials, some subsequent trials had mixed results, which led to further investigations to better understand the patient populations that may benefit and to optimize the technique. Nonetheless, the devices continue to be studied and developed, with ongoing clinical trials evaluating their safety and efficacy.

Market Dynamics:

The renal denervation devices market is expected to witness significant growth during the forecast period (2023–2030). Several factors contribute to the market growth including the rising prevalence of hypertension. Additionally, the increasing approval of innovative products is expected to propel the market growth over the forecast period. For instance, Kalos Medical, a medical device company, received a grant of Won4.67m (approximately $3.5m) to advance the development of its renal denervation medical device to treat hypertension.

Key Features of the Study:

• This report provides an in-depth analysis of the global renal denervation devices market, including market size (in US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), with 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• Key players in the global renal denervation devices market are profiled based on parameters such as company highlights, product portfolio, key highlights, financial performance, and strategies
• Key companies covered in this study include Medtronic, Recor Medical, Inc., Boston Scientific Corp, Kona Medical, Terumo Corporation, Abbott, Ablative Solutions, and others
• Insights from this report would enable marketers and management authorities of companies to make informed decisions regarding future product launches, product upgrades, market expansion, and marketing tactics.
• The global renal denervation devices market report caters to various stakeholders in the industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global renal denervation devices market

Renal Denervation Devices Market Segmentation

• By Procedure Type
• • Percutaneous Renal Denervation
  • Radiofrequency Renal Denervation
  • Ultrasound Renal Denervation
  • Others
• By End User
• • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others
• By Region
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Top Companies in the Renal Denervation Devices Market
• • Medtronic
  • Recor Medical, Inc
  • Boston Scientific Corp
  • Kona Medical
  • Terumo Corporation
  • Abbott
  • Ablative Solutions
  • Others